Patents Issued in July 6, 2017
-
Publication number: 20170189454Abstract: This disclosure provides, inter alia, systems and methods for storage and delivery of ammonia oxidizing bacteria, and preparations comprising ammonia oxidizing bacteria. The ammonia oxidizing bacteria may be provided in a container or a kit, with one or more other components that may enhance delivery. The systems and methods herein may be used, for instance, to treat diseases associated with low nitrite levels, skin diseases, and diseases caused by pathogenic bacteria.Type: ApplicationFiled: May 21, 2015Publication date: July 6, 2017Inventors: James Heywood, Spiros Jamas, David R. Whitlock, Larry Weiss
-
Publication number: 20170189455Abstract: This document provides methods and materials related to Prevotella histicola preparations. For example, Prevotella histicola preparations in the form of an oral medicament or dietary supplement (e.g., a pill, tablet, capsule) are provided. In addition, methods and materials for using a Prevotella histicola preparation provided herein as an anti-inflammatory agent are provided.Type: ApplicationFiled: December 20, 2016Publication date: July 6, 2017Inventors: Joseph A. Murray, Eric V. Marietta, Susan H. Barton, Veena Taneja, Ashutosh Mangalam
-
Publication number: 20170189456Abstract: The invention relates to a strain of Bacteroides uniformes with registration number CECT 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products. The invention further relates to the use of a strain of Bacteroides uniforms, preferably CECT 7771, or of the cellular constituents, metabolites and/or secreted molecules of said strain, or of a composition comprising same, for the prevention and/or treatment of alterations such as excess weight, obesity, adipocyte hypertrophy, hepatic steatosis or fatty liver, dyslipidemia, hyperglycemia, insulin resistance and diabetes, metabolic syndrome, hypertension, cardiovascular diseases, dysfunction of the immune system, reduced defences against infections, and imbalance in the composition of the intestinal microbiota.Type: ApplicationFiled: March 14, 2017Publication date: July 6, 2017Inventors: Yolanda Sanz Herranz, Paola Gauffin Cano, Yolanda Arlette Santacruz, Angela Moya Perez, Moises Laparra Llopis
-
Publication number: 20170189457Abstract: The present application relates to nutritional compositions comprising lactic acid-producing bacteria.Type: ApplicationFiled: March 22, 2017Publication date: July 6, 2017Inventors: Sean Farmer, David Keller, Andrew R. Lefkowitz
-
Publication number: 20170189458Abstract: It is an object of the present invention to provide a lactic acid bacterial immunopotentiating activity-increasing composition that increases the immunopotentiating activity of lactic acid bacteria having immunopotentiating activity; and a method for increasing the immunopotentiating activity of lactic acid bacteria using the composition; and a composition comprising both of lactic acid bacteria having an immunopotentiating activity and a lactic acid bacterial immunopotentiating activity-increasing composition, wherein the immunopotentiating activity of the lactic acid bacteria is increased. The present invention relates to a composition comprising lactic acid bacteria having an immunopotentiating activity and a lactic acid bacterial immunopotentiating activity-increasing composition comprising an ester compound of a polyol and a saturated fatty acid as an active ingredient.Type: ApplicationFiled: May 29, 2015Publication date: July 6, 2017Applicant: KIRIN COMPANY, LIMITEDInventors: Masaya KANAYAMA, Kyoko TAZUMI
-
Publication number: 20170189459Abstract: The present invention relates to a novel bacteriophage ?CJ24 (KCCM11462P) and a composition comprising the same as an active component. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic E. coli of birds by using the bacteriophage ?CJ24 (KCCM11462P) or the composition.Type: ApplicationFiled: April 14, 2015Publication date: July 6, 2017Applicant: CJ CHEILJEDANG CORPORATIONInventors: Eun Mi SHIN, Gi Duk BAE, Jae Won KIM
-
Publication number: 20170189460Abstract: The present invention relates to a novel bacteriophage ?CJ26 (KCCM11464P) and a composition comprising the same as an active ingredient. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by Salmonella by using the bacteriophage ?CJ26 (KCCM11464P) or the composition.Type: ApplicationFiled: April 14, 2015Publication date: July 6, 2017Applicant: CJ CHEILJEDANG CORPORATIONInventors: Eun Mi SHIN, Bo Kyung SON, Gi Duk BAE, Jae Won KIM
-
METHOD OF PREPARING FERMENTED CRUDE EXTRACT HAVING ANGIOTENSIN CONVERTING ENZYME INHIBITING ACTIVITY
Publication number: 20170189461Abstract: This invention is related to a method of preparing a fermented crude extract having angiotensin converting enzyme inhibiting activity. The method comprises the following steps. A material is dried, milled, and then mixed with water in a weight ratio of 1:11 to form a mixture solution. 0.1 vol % ?-amylase is used to perform hydrolysis at 95° C. for 1 hour. 0.1 vol % glucoamylase is used to perform hydrolysis at 65° C. for 4 hours. A lactic acid bacterium is added in a culture medium containing the mixture solution to perform fermentation for 24 hours. The culture medium is centrifuged to take the supernatant thereof, and the supernatant is boiled for 20 minutes. The supernatant is filtered to obtain a fermented crude extract having angiotensin converting enzyme inhibiting activity.Type: ApplicationFiled: December 31, 2015Publication date: July 6, 2017Inventors: SHU-CHEN WANG, PIN-DER DUH, SHIH-YING CHEN, CHEN-KAI CHANG, JUNG-TSAI CHEN, CHIH-KUANG CHIU -
Publication number: 20170189462Abstract: A method for producing powderized cannabis oil, and the resulting powderized cannabis oil, in which concentrated cannabis oil is mixed with and absorbed by a modified starch powder, preferably maltodextrin, in a ratio of at least three grams of starch powder for every one-eighth of a gram of cannabis oil is disclosed. Further disclosed are beverages, baked goods and single-serve beverage brewing cartridges utilizing or incorporating the powderized cannabis oil to create human-consumable products that contain an emulsified, tasteless, and odorless dose of cannabis oil.Type: ApplicationFiled: March 22, 2017Publication date: July 6, 2017Applicant: ERS Holdings, LLCInventors: Ross M. Franklin, Ed Rosenthal, Rachel M. Franklin
-
Publication number: 20170189463Abstract: A method for producing powderized cannabis oil, and the resulting powderized cannabis oil, in which concentrated cannabis oil is mixed with and absorbed by a modified starch powder, preferably maltodextrin, in a ratio of at least three grams of starch powder for every one-eighth of a gram of cannabis oil is disclosed. Further disclosed are beverages, baked goods and single-serve beverage brewing cartridges utilizing or incorporating the powderized cannabis oil to create human-consumable products that contain an emulsified, tasteless, and odorless dose of cannabis oil.Type: ApplicationFiled: March 22, 2017Publication date: July 6, 2017Applicant: ERS Holdings, LLCInventors: Ross M. Franklin, Ed Rosenthal, Rachel M. Franklin
-
Publication number: 20170189464Abstract: Disclosed are a method for preparing a ginseng polysaccharide for immune stimulation and a ginseng polysaccharide for immune stimulation prepared from the preparation method, the method comprising the steps of (1) adding ingredients; (2) performing an extraction; (3) performing a first filtration and cooling; (4) performing a second filtration; (5) performing a first concentration; (6) adding a concentrate to a fermentation alcohol; (7) separating into a supernatant and a precipitate; (8) collecting the precipitate; (9) dissolving in water; (10) performing a second concentration; (11) cold ageing; (12) performing a third concentration; (13) sterilizing; and (14) packaging into a product of the ginseng polysaccharide for immune stimulation in the form of a concentrate.Type: ApplicationFiled: April 27, 2015Publication date: July 6, 2017Applicant: HEALTH BIO MAD CO., LTD.Inventors: Seung Hui LEE, Gap Sun PARK, Geum Hui LEE
-
Publication number: 20170189465Abstract: With the object of providing a novel anti-hallucination agent capable of suppressing, treating or preventing a hallucinatory symptom, the anti-hallucination agent of the invention contains an Atractylodes-derived crude drug as an active ingredient or contains a compound represented by the following formula (Ia), a stereoisomer thereof or a salt thereof as an active ingredient: in the formula, the double lines consisting of a solid line and a broken line represent a single bond or a double bond; R1 represents a hydrogen atom or a hydroxyl group, with the proviso that R1 does not exist when the carbon atom to which R1 is attached is linked to one of the neighboring carbon atoms through a double bond; R2 represents a hydrogen atom or is combined with R3 to represent a cyclic group which may have a substituent; and R3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms which may have a substituent or is combined with R2 to represent a cyclic group which may have a substituent.Type: ApplicationFiled: March 26, 2015Publication date: July 6, 2017Applicant: Kracie Pharma, Ltd.Inventors: Hisayoshi Norimoto, Chiaki Murayama, Seiwa Michihara
-
Publication number: 20170189466Abstract: The present invention relates to compositions comprising black cumin (Nigelia sativa seed) oil, olive oil, tea tree (Melaleuca alternifolia) oil, cocoa butter, vitamin A or a derivative thereof, and vitamin B12 or a derivative thereof. The compositions of the present invention can be advantageously used in the in the treatment of dermatological conditions, disorders or diseases, in particular inflammatory dermatological diseases such as psoriasis.Type: ApplicationFiled: February 21, 2017Publication date: July 6, 2017Inventor: Thaher Kamal
-
Publication number: 20170189467Abstract: A composition for enhancement of ability to concentrate and method of improving ability to concentrate using alanylglutamine or a salt of alanylglutamine as an active ingredient.Type: ApplicationFiled: May 22, 2015Publication date: July 6, 2017Inventors: Yukihiro Hishida, Takeshi Ikeda, Ryusuke Nakagiri, Ayako Kamimura
-
Publication number: 20170189468Abstract: The purpose of the present invention is to provide a novel tissue regeneration promoter and method for promoting tissue regeneration. The present invention pertains to: a composition for promoting tissue regeneration and/or promoting cell growth, the composition containing an RGD peptide; a method for promoting tissue regeneration and/or promoting cell growth using RGD peptide; and the like.Type: ApplicationFiled: June 18, 2015Publication date: July 6, 2017Inventors: Yoshiro Niitsu, Akihiro Yoneda
-
Publication number: 20170189469Abstract: Medical devices comprising an anti-connexin agent suitable for introduction into a subject.Type: ApplicationFiled: February 3, 2017Publication date: July 6, 2017Inventors: David BECKER, Colin GREEN, Bradford DUFT
-
Publication number: 20170189470Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.Type: ApplicationFiled: March 15, 2017Publication date: July 6, 2017Inventors: Zhaolin Wang, Ping Ye, Alonso Ricardo, Kristopher Josephson, Paul Anderson, Michelle Denise Hoarty, Zhong Ma, Nathan Ezekiel Nims, Eberhard Schneider, Gregor Schurmann, Peter Wagner, Douglas A. Treco, Hong Zheng, Daniel Elbaum, Nicolas Cedric Boyer
-
Publication number: 20170189471Abstract: The invention provides methods for treating fibrosis and/or cancer in a subject in need thereof. The methods include providing a composition comprising an inhibitor of IL-4/IL-13 receptor function and administering an effective amount of the composition to the subject to treat fibrosis and/or cancer.Type: ApplicationFiled: March 15, 2017Publication date: July 6, 2017Applicants: Cedars-Sinai Medical Center, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ramachandran Murali, Aida Habtezion, Stephen J. Pandol
-
Publication number: 20170189472Abstract: Non-toxic aqueous compositions are provided having antibacterial activity. Specifically, the invention provides aqueous alkyl glycoside or saccharide alkyl ester compositions which meet the antimicrobial effectiveness test criteria set forth in USP 31 <51> in preventing growth of specified bacteria and fungi.Type: ApplicationFiled: March 21, 2017Publication date: July 6, 2017Inventor: Edward T. Maggio
-
Publication number: 20170189473Abstract: A composition containing wall teichoic acid-attached peptidoglycan (WTA-PGN) as an active ingredient, a method for preventing or treating Staphylococcus aureus infectious diseases using the composition, and a method for preparing a soluble WTA-PGN which can be used as an active ingredient in the composition are provided. The composition of the present invention can be effectively used for preventing or treating Staphylococcus aureus infectious diseases by opsonophagocytosis due to antigen-antibody reaction and neutrophil-mediated phagocytosis due to T cell activation at the early stage of infection.Type: ApplicationFiled: May 29, 2015Publication date: July 6, 2017Applicants: GREEN CROSS CORPORATION, PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATIONInventors: Bok Luel LEE, Min Ja LEE, Jong-Ho LEE, Min Young SEONG, Dong Ho AHN, Kazue TAKAHASHI, Kenji KUROKAWA
-
Publication number: 20170189474Abstract: The present invention provides for methods and systems for the treatment and diagnosis of Hirschsprung-associated enterocolitis. Treatment of Hirschsprung-associated enterocolitis can include providing and administering an antifungal agent or a combination of an antifungal agent and an antibiotic. Diagnosis of Hirschsprung-associated enterocolitis can include the detection of fungal species by way of qPCR.Type: ApplicationFiled: March 16, 2017Publication date: July 6, 2017Applicant: Cedars-Sinai Medical CenterInventor: Philip K. FRYKMAN
-
Publication number: 20170189475Abstract: The present invention relates to the treatment of patients with pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated.Type: ApplicationFiled: August 4, 2014Publication date: July 6, 2017Inventors: Peter Wehling, Julio Reinecke
-
Publication number: 20170189476Abstract: The present invention relates to a fusion protein composed of the extracellular domain of PD-L1 and a modified immunoglobulin Fc region. The extracellular domain of PD-L1 and a fragment thereof have excellent immunomodulatory activity, and can be used as an immunomodulatory agent if a modified immunoglobulin Fc region is coupled thereto. Accordingly, the PD-L1 fusion protein according to the present invention demonstrated its excellent effect in disease models of inflammatory bowel disease, colitis, psoriasis, asthma and arthritis, and thus can be very effectively used for the treatment of such diseases.Type: ApplicationFiled: May 26, 2015Publication date: July 6, 2017Applicants: GENEXINE, INC., POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Young Chul SUNG, Ji Yeung LEE, Mi-Young SONG, Hye Seong LIM, Byung Ha LEE
-
Publication number: 20170189477Abstract: In one aspect, the invention relates to pharmaceutical compositions comprising agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof and agents that inhibit the expression of p27Kip1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof, which are useful for inducing the formation of cochlear hair cells; and methods of treating hearing impairments or disorders using the compositions. In one aspect, the invention relates to pharmaceutical compositions comprising ?-catenin; and agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: December 29, 2016Publication date: July 6, 2017Inventors: Jian Zuo, Taosheng Chen, Brandon Walters, Bryan Kuo, Bradley Walters
-
Publication number: 20170189478Abstract: The present invention relates to various polypeptides from fish hatching fluid, their encoding nucleic acid sequences, pharmaceutical compositions comprising said polypeptides and nucleic acid molecules and their use in various medical and cosmetic applications to the skin, particularly for moisturizing skin and/or for exfoliation of the horny layer of the skin for treating or preventing skin disorders or conditions in an animal.Type: ApplicationFiled: March 6, 2017Publication date: July 6, 2017Applicant: AQUA BIO TECHNOLOGY ASAInventors: Hans Kristian LEREN, Bernt Th. WALTHER
-
Publication number: 20170189479Abstract: Disclosed herein are compositions and articles for wound healing that contain proteovesicles, comprising a syndecan polypeptide embedded in a lipid vesicle, and a PDGF polypeptide. Also disclosed is the use of these compositions to enhance wound healing.Type: ApplicationFiled: December 21, 2016Publication date: July 6, 2017Inventors: Aaron B. Baker, Subhamoy Das
-
Publication number: 20170189480Abstract: The invention provides a novel compounds derived from CD154, but without the intracellular domain. Notably, the invention provides TMZ-CD154 and a method to treat diseases in which the novel molecule TMZ-CD154 is used. In particular, TMZ-CD154 is used to modify the immune responses in patients with immune related diseases such as cancer and infectious disease. The invention also relates to a method to activate cells with the TMZ-CD154 in vitro either prior to using the activated cells for therapy or for diagnostic purposes.Type: ApplicationFiled: April 7, 2015Publication date: July 6, 2017Applicant: LOKON PHARMA ABInventor: Angelica Loskog
-
Publication number: 20170189481Abstract: The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.Type: ApplicationFiled: June 25, 2015Publication date: July 6, 2017Inventors: Yibin Kang, Yongna Xing, Liling Wan, Feng Guo
-
Publication number: 20170189482Abstract: In one aspect the present invention is directed to mutant Neutrophil Gelatinase Associated Lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: ApplicationFiled: December 12, 2016Publication date: July 6, 2017Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jonathan BARASCH, Andong QIU
-
Publication number: 20170189483Abstract: The invention is directed, in part, to the use of gelsolin to diagnose, monitor, and treat subjects with renal failure (e.g., chronic renal failure subjects on dialysis).Type: ApplicationFiled: January 17, 2017Publication date: July 6, 2017Inventors: RAVI THADHANI, THOMAS P. STOSSEL, PO-SHUN LEE, ANANTH KARUMANCHI
-
Publication number: 20170189484Abstract: The present invention relates to small peptides, derived from the N-terminal domain of CEACAM5 (carcinoembryonic antigen family member 5), with the ability to stimulate the suppressive activity of CD8+ T cells in Crohn's disease. Pharmaceutical formulations, methods to treat patients with Crohn's disease, and methods to identify candidate peptides for treatment of Crohn's disease patients, are also disclosed.Type: ApplicationFiled: May 1, 2015Publication date: July 6, 2017Inventors: Giulia RODA, Lloyd MAYER
-
Publication number: 20170189485Abstract: This application provides methods of increasing vascularization, muscle performance, muscle rehabilitation, and/or mitochondrial activity in subjects in need thereof, by administering a therapeutically effective amount of one or more agents that increases ERR? activity to the subject. Such agents can include one or more ERR? agonists. In some examples the method does not require that the subject exercise, and as such, the subject may be sedentary (such as bedridden or in a wheelchair).Type: ApplicationFiled: January 17, 2017Publication date: July 6, 2017Applicant: Salk Institute for Biological StudiesInventors: Vihang A. Narkar, Michael Downes, Ruth T. Yu, Ronald M. Evans
-
Publication number: 20170189486Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.Type: ApplicationFiled: March 16, 2017Publication date: July 6, 2017Inventors: Paul E. MORIN, Daniel COHEN, Ranjan MUKHERJEE, Timothy P. REILLY, Rose C. CHRISTIAN, Dasa LIPOVSEK, Ray CAMPHAUSEN, John KRUPINSKI
-
Publication number: 20170189487Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: April 24, 2015Publication date: July 6, 2017Inventors: Ryo Ohori, Kanta Horie
-
Publication number: 20170189488Abstract: Provided is a method for treating a peripheral nervous system damage or injury, or for regenerating peripheral nervous system tissue that involves administering to a subject in need thereof a vector that comprises polynucleotide sequences that encode vascular endothelia growth factor (VEGF) and fibroblast growth factor (FGF2) and further a polynucleotide that encodes resistance to kanamycin. A gene-therapeutic structure coding vascular endothelial growth factor (VEGF) and (FGF-2) is also provided. The gene-therapeutic structure can be administered directly to a damaged nerve and paraneural tissues both in intraoperative and post-operative period to stimulate peripheral nerve regeneration. The structure and method significantly advance existing methods for reconstructive treatment for damaged peripheral nerves.Type: ApplicationFiled: March 16, 2017Publication date: July 6, 2017Applicant: ''NEXTGEN'' COMPANY LIMITEDInventors: Artur Aleksandrovich ISAEV, Albert Anatolyevich Rizvanov, Ruslan Faridovich Masgutov, Aleksei Andreevich Bogov, IInur lldusovich Salafutdinov, Roman Vadimovich Deev, llya Yadigerovich Bozo, Igor Leonidovich Plaksa, Andrei Alekseevich Bogov
-
Publication number: 20170189489Abstract: A method of causing cardiomyocyte growth and/or differentiation, the method comprising exposing a cardiomyocyte to neuregulin (NRG) thereby activating the MAP kinase pathway in the cardiomyocyte and causing growth and/or differentiation of the cardiomyocyte. Use of neuregulin, neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins in the treatment or management of heart disease and heart failure in a mammal.Type: ApplicationFiled: August 12, 2016Publication date: July 6, 2017Inventor: Mingdong Zhou
-
Publication number: 20170189490Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.Type: ApplicationFiled: March 15, 2017Publication date: July 6, 2017Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: HUNTINGTON POTTER, GARY W. ARENDASH, STEVEN BENNETT, TIMOTHY BOYD
-
Publication number: 20170189491Abstract: Provided is a composition containing neuropeptide Y for inhibiting side effects of anticancer agents. The neuropeptide Y of the present invention exhibits an effect of mitigating side effects, especially bone marrow injury and neurological disorders, occurring due to the administration of anticancer agents, and thus may be useful as an anticancer adjuvant which may mitigate side effects of anticancer agents and enhance the effect of anticancer agents.Type: ApplicationFiled: July 14, 2015Publication date: July 6, 2017Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Jae Sung Bae, Hee Kyung Jin, Min Hee Park
-
Publication number: 20170189492Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.Type: ApplicationFiled: March 27, 2015Publication date: July 6, 2017Inventors: Anders Hasager Boss, Richard Petrucci
-
Publication number: 20170189493Abstract: The present invention provides compositions, devices, methods and processes related to the intradermal delivery of PTHrP and PTHrP analogues, particularly [Glu22,25, Leu23,28,31, Aib29, Lys26,30]hPTHrP(1-34)NH2.Type: ApplicationFiled: November 14, 2016Publication date: July 6, 2017Inventors: Gary HATTERSLEY, Kris J. HANSEN, Amy S. DETERMAN, Ying ZHANG
-
Publication number: 20170189494Abstract: A histidine-free composition comprising: a high purity factor VIII (r-factor VIII); arginine and/or sucrose; a surface-active agent to prevent or at least inhibit surface adsorption of factor VIII; an amount of calcium chloride for specific stabilization of factor VIII.Type: ApplicationFiled: March 20, 2017Publication date: July 6, 2017Applicant: OCTAPHARMA AGInventors: BRITA RIPPNER, JOSEFIN KNUTSSON, ULRIKA NILSSON, ELSA IVARSSON, ERÈNE AGERKVIST
-
Publication number: 20170189495Abstract: It is disclosed herein that microperoxidases are capable of binding carbon monoxide (CO) with high affinity and displacing CO from hemoglobin, thereby acting as CO scavengers. The present disclosure provides methods of treating carboxyhemoglobinemia (or CO poisoning) in a subject by administering a therapeutically amount of an isolated or recombinant microperoxidase. Methods of removing CO from hemoglobin in blood or tissue by administering a therapeutically amount of an isolated or recombinant microperoxidase are also described. Methods of determining the effectiveness of a microperoxidase for removing CO from hemoglobin are further described.Type: ApplicationFiled: May 19, 2015Publication date: July 6, 2017Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Mark Thomas Gladwin, Jesus Tejero Bravo
-
Publication number: 20170189496Abstract: A method for the treatment and/or the prevention of a disease or a symptom related to dysfunction of regulatory T cell immunomodulation includes administering to a subject in need thereof compositions that regulate regulatory T cell immunomodulatory function, in which the compositions may be prepared by contacting starting materials with phosphorylation pathway-related factors, the agonists or the antagonists thereof. The phosphorylation pathway-related factors are selected from: proto-oncogene protein PIM1 and the coding sequence thereof. The regulation is achieved by regulating the activity of regulators of regulatory T cells selected from the group: FOXP3, IL-2, GITR, CTLA4, and a combination thereof.Type: ApplicationFiled: March 9, 2017Publication date: July 6, 2017Applicant: Institut Pasteur of Shanghai, Chinese Academy of SciencesInventors: Bin Li, Zhiyuan Li, Fang Lin, Zhimei Gao, Zuojia Chen, Andy Tsun, Kongchen Li
-
Publication number: 20170189497Abstract: A method for treating Pompe disease including administration of recombinant human acid ?-glucosidase having optimal glycosylation with mannose-6-phosphate residues in combination with an amount of miglustat effective to maximize tissue uptake of recombinant human acid ?-glucosidase while minimizing inhibition of the enzymatic activity of the recombinant human acid ?-glucosidase is provided.Type: ApplicationFiled: December 29, 2016Publication date: July 6, 2017Inventors: Hung V. Do, Richie Khanna, Russell Gotschall
-
Publication number: 20170189498Abstract: The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be selected from the group consisting of a Gram-positive bacterium, a Gram-negative bacterium, or both. In one embodiment, the present invention is drawn to a polynucleotide encoding a Mitrecin A polypeptide, a vector comprising the polynucleotide, a host cell comprising the polynucleotide, or a composition comprising the Mitrecin A polypeptide, the polynucleotide, the vector, or the host cell.Type: ApplicationFiled: January 6, 2017Publication date: July 6, 2017Applicant: The MITRE CorporationInventor: Michael Heath FARRIS
-
Publication number: 20170189499Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.Type: ApplicationFiled: March 21, 2017Publication date: July 6, 2017Applicant: BIOM'UPInventors: Christian GAGNIEU, Patricia FOREST, Sylvain PICOT
-
Publication number: 20170189500Abstract: This invention relates to novel uses of recombinant clostridial neurotoxins exhibiting decreased duration of effect, in particular uses for the treatment of patients having experienced muscle-related disorders and/or injuries.Type: ApplicationFiled: June 12, 2015Publication date: July 6, 2017Inventors: Klaus FINK, Susanne GRAFE, Imke SCHULTZ, Susanna ROLL, Deryck JORDAN
-
Publication number: 20170189501Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.Type: ApplicationFiled: September 14, 2016Publication date: July 6, 2017Inventors: Joan M. Fallon, Matthew Heil, James Szigethy, James Fallon
-
Publication number: 20170189502Abstract: A first antigen is administered to a subject to select progenitor B cells that are suitable for subsequent production of a desirable affinity-matured antibody, and then a second antigen is administered to stimulate the expansion of B cells that produce that affinity-matured antibody. An immunization protocol is used in which two different antigens are administered (usually in series, but in some embodiment simultaneously), where the first antigen elicits an efficient germline antibody response and the second antigen elicits an efficient and desired affinity-matured antibody response.Type: ApplicationFiled: December 14, 2016Publication date: July 6, 2017Inventor: Philip Dormitzer
-
Publication number: 20170189503Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.Type: ApplicationFiled: February 11, 2015Publication date: July 6, 2017Inventors: Alan Remaley, John T. Schillerr, Marcelo Amar, Bryce Chackerian